Table 3 Predictors of response to vaccine on TP2 in multiple myeloma patients.

Age

0.269

 > 73 years (n = 20)

14 (70%)

 < 73 years (n = 22)

19 (86.4%)

Gender

1

 M (n = 23)

18 (78.3%)

 F (n = 19)

15 (78.9%)

BMI

0.130

 > 24.3 (n = 21)

19 (90.5%)

 < 24.3 (n = 21)

14 (66.7%)

Lines of therapy

0.271

 1 (n = 17)

15 (88.2%)

 > 1 (n = 25)

18 (72%)

Lymphocyte count

0.454

 > 1150/µL (n = 21)

18 (85.7%)

 < 1150/µL (n = 21)

15 (71.4%)

Time from diagnosis to vaccination

1

 > 72 months (n = 21)

17 (81%)

 < 72 months (n = 21)

16 (76.2%)

Time from the start of ongoing therapy to vaccination

1

 > 9 months (n = 20)

16 (80%)

 < 9 months (n = 22)

17 (77.3%)

Treatment

0.003

 Daratumumab-based (n = 14)

7 (50%)

 PI-based/Imids-based alone or in combo without daratumumab (n = 28)

26 (92.9%)